摘要:
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R4, R6, X, Y and Z are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.
摘要:
The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.
摘要:
Substituted aryl 1,4-pyrazine derivatives of formula I as defined herein and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
摘要:
The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
摘要:
This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.
摘要:
Substituted aryl pyrazine derivatives of the formula I as defined herein, and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
摘要:
The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
摘要:
The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: ##STR1## or steroisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent, wherein:R.sup.1 is C.sub.1-3 alkyl substituted with 1-7 halogen;R.sup.2 is optionally substituted C.sub.1-5 alkyl, optionally substituted C.sub.2-5 alkenyl, or optionally substituted C.sub.2-5 alkynyl;R.sup.3, at each occurrence, is independently selected from C.sub.1-4 alkyl, OH, C.sub.1-4 alkoxy, F, Cl, Br, I, NR.sup.5 R.sup.5a, NO.sub.2, CN, C(O)R.sup.6, NHC(O)R.sup.7, and NHC(O)NR.sup.5 R.sup.5a ;R.sup.5 and R.sup.5a are independently selected from H and C.sub.1-3 alkyl;R.sup.6 is selected from H, OH, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, and NR.sup.5 R.sup.5a ;R.sup.7 is selected from C.sub.1-3 alkyl and C.sub.1-3 alkoxy;R.sup.8 is selected from H, C.sub.3-5 cycloalkyl, and C.sub.1-3 alkyl; and,n is selected from 0, 1, 2, 3, and 4.
摘要翻译:本发明涉及式I的4,4-二取代-3,4-二氢-2(1H) - 喹唑啉酮:或其立体异构体形式,立体异构混合物或其药学上可接受的盐形式,其可用作HIV逆转录酶的抑制剂 ,以及包含其的药物组合物和诊断试剂盒,及其用于治疗病毒感染的方法或作为测定标准品或试剂,其中:R1是被1-7个卤素取代的C1-3烷基; R 2是任选取代的C 1-5烷基,任选取代的C 2-5烯基或任选取代的C 2-5炔基; R 3在每次出现时独立地选自C 1-4烷基,OH,C 1-4烷氧基,F,Cl,Br,I,NR 5 R 5a,NO 2,CN,C(O)R 6,NHC(O) (O)NR5R5a; R5和R5a独立地选自H和C1-3烷基; R6选自H,OH,C1-4烷基,C1-4烷氧基和NR5R5a; R 7选自C 1-3烷基和C 1-3烷氧基; R8选自H,C3-5环烷基和C1-3烷基; 并且n选自0,1,2,3和4。
摘要:
The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones of formula I: ##STR1## or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
摘要:
This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.